Objective: To discuss the clinical effect of Kangmin Zhike mixture by oral taking or aerosol inhalation in treating children with cough variant asthma (CVA) and its influence to quality of life. Method: Eighty seven patients were randomly divided into control group (42 cases) and observation group (45 cases) by random number table. Patients in control group received montelukast sodium chewable tablets before sleeping at night

4 mg for children who were less than 6 years old and 5 mg for children who were more than 6 years old

1 time/day. Based on the treatment of control group

patients in observation group received additional Kangmin Zhike mixture by oral taking or aerosol inhalation. The treatment course was 4 weeks in both groups. Before and after treatment

scores of cough

ecphysesis

throat itching

expectoration and other symptoms were graded.Leicester cough questionnaire (LCQ) was made. And levels of the total IgE and peripheral blood eosinophils (EOS) in serum were detected. Result: Ridit analysis showed that

the clinical effect in observation group was superior to that in control group (P<0.05). Scores of nighttime cough

daytime cough and ecphysesis in observation groups were less than those in control group (P<0.01). Three dimension scores and total scores for LCQ in observation group were less than those in control group (P<0.01). Levels of the total IgE and EOS in serum were lower than those in control group (P<0.05). Conclusion: Kangmin Zhike mixture by oral taking and aerosol inhalation in the treatment of CVA can relieve inflammatory response in airway

ameliorate cough

and improve quality of life for patients

with significant clinical effect.